Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
暂无分享,去创建一个
H. Dombret | A. Stamatoullas | P. Fenaux | E. Deconinck | L. Adès | X. Thomas | C. Récher | J. Delaunay | N. Vey | M. Hunault-Berger | J. Micol | E. Raffoux | L. Degos | P. Bories | P. Hirsch | C. Pautas | J. Marolleau | D. Bordessoule | Ramy Rahmé | N. Fegueux | C. Mariette | R. Rahmé | N. Vey
[1] J. Bergeron,et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan‐Canadian epidemiological study , 2014, British journal of haematology.
[2] Gareth J. Morgan,et al. A gene expression signature for high-risk multiple myeloma , 2014, Leukemia.
[3] W. Wiktor-Jedrzejczak,et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia , 2014, Cancer.
[4] K. Anderson,et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. , 2014, Blood.
[5] D. Gibbons,et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy , 2014, Proceedings of the National Academy of Sciences.
[6] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[7] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[8] G. Oliveira,et al. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation , 2014, Immunological reviews.
[9] Sadik H. Kassim,et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.
[10] K. Coombes,et al. Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells , 2013, PloS one.
[11] H. Goldschmidt,et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.
[12] B. B. Weitner,et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. , 2013, Leukemia research.
[13] Martin C. Müller,et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. , 2013, Blood.
[14] G. Hoser,et al. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice , 2013, Leukemia.
[15] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[16] B. Pégourié,et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. , 2013, Blood.
[17] N. Munshi,et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. , 2013, Blood.
[18] R. Larson,et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide , 2012, Journal of Hematology & Oncology.
[19] M. Voso,et al. Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS) , 2012 .
[20] David A. Williams,et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. , 2012, Blood.
[21] J. Rogers,et al. Differentiation syndrome in patients with acute promyelocytic leukemia , 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[22] Ash A. Alizadeh,et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia , 2012, Haematologica.
[23] P. L. Bergsagel,et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.
[24] Seung-Mo Hong,et al. Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer , 2011, Clinical Cancer Research.
[25] B. Barlogie,et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma , 2011, International journal of hematology.
[26] John Crowley,et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. , 2011, Blood.
[27] G. Morgan,et al. A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment , 2011, Clinical Cancer Research.
[28] M. Schymura,et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. , 2011, Blood.
[29] M. Höglund,et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry , 2011, Leukemia.
[30] A. Ganser,et al. Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. , 2011, Human gene therapy.
[31] J. Mackey,et al. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. , 2011, The American journal of pathology.
[32] E. Estey,et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[33] P. L. Bergsagel,et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) , 2010, Leukemia.
[34] F. Roudot-thoraval,et al. CD4+CD25+ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation , 2010, Science Translational Medicine.
[35] T. Skorski,et al. Chronic myeloid leukemia: mechanisms of blastic transformation. , 2010, The Journal of clinical investigation.
[36] H. Heslop,et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.
[37] D. Shen,et al. Identification of transgelin‐2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis , 2010, Cancer science.
[38] R. Arceci. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome , 2010 .
[39] D. Cella,et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.
[40] A. Ganser,et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. , 2009, The Lancet. Oncology.
[41] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[42] R. Arceci. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience , 2009 .
[43] Laurence Lodé,et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Cazzola,et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] L. Staudt,et al. IRF4 addiction in multiple myeloma , 2008, Nature.
[46] Jin Man Kim,et al. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. , 2008, Cancer genetics and cytogenetics.
[47] T. Holyoake,et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors , 2008, Leukemia.
[48] H. Dombret,et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.
[49] J. Wagner,et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. , 2006, Blood.
[50] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[51] H. Dombret,et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[53] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[54] M. Beksac,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[55] B. Neel,et al. Phosphatidylinositol 3-Kinase p85α Subunit-Dependent Interaction with BCR/ABL-Related Fusion Tyrosine Kinases: Molecular Mechanisms and Biological Consequences , 2005, Molecular and Cellular Biology.
[56] S. Marley,et al. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. , 2005, Clinical science.
[57] S. Payne,et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. , 2005, Cancer research.
[58] R. Salgia,et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. , 2005, Blood.
[59] T. Barbui,et al. Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group. , 2004 .
[60] M. Guillier,et al. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. , 2004, Biochemical and biophysical research communications.
[61] F. Mandelli,et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.
[62] A. Dalgleish,et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] D. Klatzmann,et al. Efficient transduction and selection of human T‐lymphocytes with bicistronic Thy1/HSV1‐TK retroviral vector produced by a human packaging cell line , 2004, The journal of gene medicine.
[64] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] E. Sausville,et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. , 2003, Molecular cancer therapeutics.
[66] T. Kuzel,et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. , 2003, Experimental hematology.
[67] P. Rebulla,et al. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies , 2003, Transfusion.
[68] N. Kröger,et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias , 2003, Leukemia.
[69] T. Skorski,et al. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571 , 2002, Oncogene.
[70] Craig W. Reynolds,et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.
[71] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[72] A. Subramanian,et al. Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. , 2000, The Journal of biological chemistry.
[73] J. Miguel,et al. Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia , 1998 .
[74] J. Miguel,et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1998, Blood.
[75] T. Barbui,et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.
[76] Marietta Y. W. T. Lee,et al. Identification of DNA replication and cell cycle proteins that interact with PCNA. , 1997, Nucleic acids research.
[77] B. Calabretta,et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.
[78] C. Bloomfield,et al. All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.
[79] P. Lansdorp,et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. , 1997, Blood.
[80] V. Broudy,et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. , 1995, The Journal of clinical investigation.